Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

Asuka Katsuki, Reiji Yoshimura, Taro Kishi, Hikaru Hori, Wakako Umene-Nakano, Atsuko Ikenouchi-Sugita, Kenji Hayashi, Kiyokazu Atake, Nakao Iwata, Jun Nakamura

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients. Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively. Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG). Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels. Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.

Original languageEnglish
Pages (from-to)155-163
Number of pages9
JournalCNS Spectrums
Volume17
Issue number3
DOIs
Publication statusPublished - 01-09-2012

Fingerprint

Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Catecholamines
Serum
Genes
Homovanillic Acid
mirtazapine
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Enzyme-Linked Immunosorbent Assay
Genotype
High Pressure Liquid Chromatography
Depression

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Katsuki, Asuka ; Yoshimura, Reiji ; Kishi, Taro ; Hori, Hikaru ; Umene-Nakano, Wakako ; Ikenouchi-Sugita, Atsuko ; Hayashi, Kenji ; Atake, Kiyokazu ; Iwata, Nakao ; Nakamura, Jun. / Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). In: CNS Spectrums. 2012 ; Vol. 17, No. 3. pp. 155-163.
@article{1ebc577f291c4dcd832ab0503b7bac39,
title = "Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)",
abstract = "Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients. Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively. Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG). Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels. Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.",
author = "Asuka Katsuki and Reiji Yoshimura and Taro Kishi and Hikaru Hori and Wakako Umene-Nakano and Atsuko Ikenouchi-Sugita and Kenji Hayashi and Kiyokazu Atake and Nakao Iwata and Jun Nakamura",
year = "2012",
month = "9",
day = "1",
doi = "10.1017/S109285291200051X",
language = "English",
volume = "17",
pages = "155--163",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "3",

}

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). / Katsuki, Asuka; Yoshimura, Reiji; Kishi, Taro; Hori, Hikaru; Umene-Nakano, Wakako; Ikenouchi-Sugita, Atsuko; Hayashi, Kenji; Atake, Kiyokazu; Iwata, Nakao; Nakamura, Jun.

In: CNS Spectrums, Vol. 17, No. 3, 01.09.2012, p. 155-163.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

AU - Katsuki, Asuka

AU - Yoshimura, Reiji

AU - Kishi, Taro

AU - Hori, Hikaru

AU - Umene-Nakano, Wakako

AU - Ikenouchi-Sugita, Atsuko

AU - Hayashi, Kenji

AU - Atake, Kiyokazu

AU - Iwata, Nakao

AU - Nakamura, Jun

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients. Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively. Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG). Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels. Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.

AB - Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients. Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively. Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG). Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels. Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.

UR - http://www.scopus.com/inward/record.url?scp=84869232094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869232094&partnerID=8YFLogxK

U2 - 10.1017/S109285291200051X

DO - 10.1017/S109285291200051X

M3 - Article

C2 - 22883353

AN - SCOPUS:84869232094

VL - 17

SP - 155

EP - 163

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 3

ER -